Literature DB >> 20565461

Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Arduino A Mangoni1, Richard J Woodman, Paraskevi Gaganis, Andrew L Gilbert, Kathleen M Knights.   

Abstract

AIMS: We studied the association between either non-selective NSAIDs (ns-NSAIDs), selective COX-2 inhibitors, or any NSAID and risk of incident myocardial infarction (MI) and heart failure (HF), and all-cause mortality in elderly subjects.
METHODS: We conducted a retrospective nested case-control study on Australian veterans using nationwide hospital admission and pharmacy dispensing data. We estimated adjusted odds ratios (OR) with 95% confidence intervals (CI) for the risk of events for three different measures of prescription supply exposure over the last 2 years: (i) supplied at least once, (ii) supply frequency: supplied more than twice within the last 30 days, once or twice within the last 30 days, and once or more 30 days to 2 years and (iii) total supplies.
RESULTS: We identified 83 623 cases and 1 662 099 matched controls (1:20) contributing 3 862 931 persons-years of observation. NSAID use at least once within the last 2 years did not significantly affect the risk of MI (OR 1.00, 95% CI 0.96, 1.04) but was associated with a mildly reduced risk of HF (OR 0.95, 95% CI 0.92, 0.98). There was a reduced all-cause mortality with at least one supply of either ns-NSAIDs (OR 0.94, 95% CI 0.90, 0.97), selective COX-2 inhibitors (OR 0.90, 95% CI 0.88, 0.93), or any NSAID (OR 0.87, 95% CI 0.85, 0.90). Risk of death was also inversely associated with the number of prescription supplies.
CONCLUSIONS: NSAID use is not associated with an increased risk of incident MI and HF but is associated with a reduction in all-cause mortality in Australian veterans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20565461      PMCID: PMC2883762          DOI: 10.1111/j.1365-2125.2010.03627.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  85 in total

Review 1.  Anti-inflammatory drugs and atherosclerosis.

Authors:  Sami P Moubayed; Therese M Heinonen; Jean-Claude Tardif
Journal:  Curr Opin Lipidol       Date:  2007-12       Impact factor: 4.776

2.  Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups.

Authors:  Daniel H Solomon; Robert J Glynn; Kenneth J Rothman; Sebastian Schneeweiss; Soko Setoguchi; Helen Mogun; Jerry Avorn; Til Stürmer
Journal:  Arthritis Rheum       Date:  2008-08-15

3.  The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people.

Authors:  Emil Loldrup Fosbøl; Gunnar H Gislason; Søren Jacobsen; Steen Z Abildstrom; Morten Lock Hansen; Tina Ken Schramm; Fredrik Folke; Rikke Sørensen; Jeppe N Rasmussen; Lars Køber; Mette Madsen; Christian Torp-Pedersen
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-08       Impact factor: 2.890

4.  Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.

Authors:  Patricia McGettigan; Pearline Han; Lisa Jones; Diana Whitaker; David Henry
Journal:  Br J Clin Pharmacol       Date:  2008-04-01       Impact factor: 4.335

5.  Heart failure-related hospitalization in the U.S., 1979 to 2004.

Authors:  Jing Fang; George A Mensah; Janet B Croft; Nora L Keenan
Journal:  J Am Coll Cardiol       Date:  2008-08-05       Impact factor: 24.094

6.  Possible arrhythmiogenic mechanism produced by ibuprofen.

Authors:  Zhi-fang Yang; Hong-wei Wang; Yan-qian Zheng; Yin Zhang; Yuan-mou Liu; Ci-zhen Li
Journal:  Acta Pharmacol Sin       Date:  2008-04       Impact factor: 6.150

7.  C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study.

Authors:  Eric S Williams; Sanjiv J Shah; Sadia Ali; Bee Ya Na; Nelson B Schiller; Mary A Whooley
Journal:  Eur J Heart Fail       Date:  2007-12-21       Impact factor: 15.534

Review 8.  Inflammation at the molecular interface of atherogenesis: an anthropological journey.

Authors:  Brian D Lamon; David P Hajjar
Journal:  Am J Pathol       Date:  2008-11       Impact factor: 4.307

9.  Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality.

Authors:  Aditya Bardia; Jon O Ebbert; Robert A Vierkant; Paul J Limburg; Kristin Anderson; Alice H Wang; Janet E Olson; Celine M Vachon; James R Cerhan
Journal:  J Natl Cancer Inst       Date:  2007-06-06       Impact factor: 13.506

10.  Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction.

Authors:  Hugues Blangy; Nicolas Sadoul; Brigitte Dousset; Anca Radauceanu; Renaud Fay; Etienne Aliot; Faiez Zannad
Journal:  Europace       Date:  2007-05-24       Impact factor: 5.214

View more
  14 in total

1.  All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study.

Authors:  Stephen J Kerr; Debra S Rowett; Geoffrey P Sayer; Susan D Whicker; Deborah C Saltman; Andrea Mant
Journal:  Br J Clin Pharmacol       Date:  2010-05-06       Impact factor: 4.335

Review 2.  Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults.

Authors:  Sheena Derry; Philip J Wiffen; R Andrew Moore; Ewan D McNicol; Rae F Bell; Daniel B Carr; Mairead McIntyre; Bee Wee
Journal:  Cochrane Database Syst Rev       Date:  2017-07-12

Review 3.  Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults.

Authors:  Sheena Derry; Philip J Wiffen; Winfried Häuser; Martin Mücke; Thomas Rudolf Tölle; Rae F Bell; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-03-27

Review 4.  Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies.

Authors:  Patompong Ungprasert; Narat Srivali; Charat Thongprayoon
Journal:  Clin Cardiol       Date:  2015-12-31       Impact factor: 2.882

5.  Meloxicam and risk of myocardial infarction: a population-based nested case-control study.

Authors:  Deepan Dalal; Maureen Dubreuil; Christine Peloquin; Tuhina Neogi; Yuqing Zhang; Hyon Choi; David Felson
Journal:  Rheumatol Int       Date:  2017-10-13       Impact factor: 2.631

6.  Microglial cathepsin B contributes to the initiation of peripheral inflammation-induced chronic pain.

Authors:  Li Sun; Zhou Wu; Yoshinori Hayashi; Christoph Peters; Makoto Tsuda; Kazuhide Inoue; Hiroshi Nakanishi
Journal:  J Neurosci       Date:  2012-08-15       Impact factor: 6.167

7.  Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study.

Authors:  Jean-Pascal Fournier; Agnès Sommet; Robert Bourrel; Stéphane Oustric; Atul Pathak; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2012-04-15       Impact factor: 2.953

Review 8.  The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review.

Authors:  Waheed Asghar; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2014-12-17       Impact factor: 4.473

Review 9.  Defining a reference set to support methodological research in drug safety.

Authors:  Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 10.  Non-steroidal anti-inflammatory drugs in the pharmacological management of osteoarthritis in the very old: prescribe or proscribe?

Authors:  Christian Cadet; Emmanuel Maheu
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-18       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.